According to the TMA assay, the results showed that 154/247 breast cancer patients (62.3%) were strongly stained with anti-SCYL1 (the right 4 panels, Figure 2B), and 93 tumor samples (37.7%) had weak or no staining (the left 4 panels, Figure 2B). Here, SCYL1 is linked to breast cancer.